NSE LUPIN · BSE 500257 · Biotechnology & Drugs · NIFTY 500

Lupin Share Price

Market closed · NSE price as of Mon 28 Sep
₹2,062.00 ▼ −₹29.91 · 1.43%
Day range · 28 Sep
₹2,057.00Low₹2,097.15High
52-week range
₹1,900.30Low · 28 Oct 2025₹2,530.00High · 16 Jul 2026

Lupin Overview

Where the price stands, how it has moved and how it sits against its averages.

Lupin shares last traded at ₹2,062.00 on the NSE, down 1.43% on the day. That is 18.5% below the 52-week high of ₹2,530.00 and 8.5% above the 52-week low of ₹1,900.30. The stock trades at 17.05× earnings, below the sector average of 33.72. Its market value is ₹94,288 Cr.

NSE closing prices — daily for the last year, weekly before that — ending at the latest price (Mon 28 Sep). Hover, tap or use the arrow keys to read a day.

Price returns

1 Day▼ −1.43%
1 Week▼ −2.94%
This month▼ −5.78%
3 Months▼ −12.01%
6 Months▼ −11.68%
This year▼ −2.25%
1 Year▲ +7.41%

Share price growth a year (CAGR): 3 years ▲ +23.4% · 5 years ▲ +17.4% · 10 years ▲ +3.3%

Against the market: 1 Month ▲ +0.73% · 3 Months ▼ −6.86% · 6 Months ▼ −10.78% · This year ▲ +14.37% · 1 Year ▲ +17.02%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Fri 16 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 0 of 6

  1. 100-day average₹2,293.39 ▼ price 10.1% below
  2. 300-day average₹2,254.82 ▼ price 8.6% below
  3. 50-day average₹2,248.84 ▼ price 8.3% below
  4. 20-day average₹2,114.50 ▼ price 2.5% below
  5. 5-day average₹2,111.00 ▼ price 2.3% below
  6. 10-day average₹2,093.93 ▼ price 1.5% below
  7. Today's price₹2,062.00

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Lupin Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
27,958
Net profit₹ crore · losses below zero
−1,528
5,333

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹27,958 Cr ▲ +23.1% ₹5,333 Cr 19.1% ₹116.44 ₹18.00
FY 2025 ₹22,708 Cr ▲ +13.5% ₹3,282 Cr 14.5% ₹71.69 ₹12.00
FY 2024 ₹20,011 Cr ▲ +20.2% ₹1,914 Cr 9.6% ₹41.87 ₹8.00
FY 2023 ₹16,642 Cr ▲ +1.4% ₹430 Cr 2.6% ₹9.41 ₹4.00
FY 2022 ₹16,405 Cr ▲ +8.2% −₹1,528 Cr −9.3% −₹33.65 ₹4.00
FY 2021 ₹15,163 Cr ▼ −1.4% ₹1,217 Cr 8.0% ₹26.72 ₹6.50
FY 2020 ₹15,375 Cr — −₹269 Cr −1.8% −₹8.82 ₹6.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
41%
59%
  • Total assets₹38,365 Cr
  • Total liabilities₹15,917 Cr
  • Shareholders' equity₹22,448 Cr
  • Total debt₹6,616 Cr
  • Cash & investments₹7,948 Cr
  • Current ratio1.90×
  • Revenue growth, 5 yr13.02% a year
  • EPS growth, 5 yr34.23% a year
  • Operating margin (TTM)23.01%
  • Net margin (TTM)18.52%

Cash flow — FY26

Operating activities
▲ ₹7,335 Cr
Investing activities
▼ −₹3,865 Cr
Financing activities
▼ −₹846 Cr
Free cash flow
▲ ₹5,280 Cr
Net change in cash
▲ ₹2,624 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue15,374.7615,162.9616,405.4816,641.6620,010.8222,707.9027,958.03
Cost of revenue5,949.696,068.557,636.627,862.827,825.478,121.718,735.78
Gross profit9,425.079,094.418,768.868,778.8412,185.3514,586.1919,222.25
Operating expenses14,715.6813,472.1417,799.4715,760.0117,402.9318,576.0721,446.68
Operating income659.081,690.82−1,393.99881.652,607.894,131.836,511.35
Depreciation970.22887.41818.50841.31995.561,087.861,262.30
Profit before tax757.231,676.45−1,372.21716.492,422.274,015.006,872.55
Tax1,157.11448.52137.15268.80486.70708.741,517.08
Net profit−269.391,216.53−1,528.04430.081,914.483,281.625,332.84
EPS (₹)−8.8226.72−33.659.4141.8771.69116.44
Dividend per share (₹)6.006.504.004.008.0012.0018.00

Lupin vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Lupin This stock ₹2,062.00 ▼ −1.43% ₹94,288 Cr 17.05 4.20 12.70% 18.52% 0.87%
Sun Pharmaceutical Industries ₹1,840.00 ▼ −0.73% ₹4,41,467 Cr 38.40 5.55 14.22% 19.12% 0.83%
Divi's Laboratories ₹9,531.50 ▼ −0.82% ₹2,53,031 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,869.40 ▼ −2.32% ₹1,85,210 Cr 72.73 19.22 23.00% 15.29% 0.80%
Cipla ₹1,388.90 ▼ −0.59% ₹1,12,205 Cr 27.57 3.33 14.47% 13.74% 0.92%
Zydus Lifesciences ₹1,212.00 ▲ +0.83% ₹1,20,897 Cr 21.19 4.24 17.90% 18.51% 0.09%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Lupin shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
46.9%
22.4%
14.8%
15.9%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter46.90%46.89%46.86%46.85% ▼ −0.01 pts
FII20.50%21.50%21.70%22.42% ▲ +0.72 pts
MF20.57%18.01%16.93%14.84% ▼ −2.09 pts
Other12.03%13.60%14.51%15.89% ▲ +1.38 pts

Lupin Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

LupinBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
17.05
▼ 49% below the sector average of 33.72
P/E, 12-month rangeLow 18.71 · high 463.08
0%
Today's P/E sits 0% of the way from its low to its high
P/BPrice ÷ book value per share
4.20
P/SMarket cap ÷ last 12 months' revenue
3.15
P/CFPrice ÷ cash flow per share
13.51
PEGP/E ÷ earnings growth rate
0.12

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
74.49%
▲ above its 5-yr average of 61.26%
Operating marginKept after running costs
23.01%
▲ above its 5-yr average of 12.28%
Pre-tax marginKept before tax
24.94%
▲ above its 5-yr average of 12.20%
Net marginKept as profit
18.52%
▲ above its 5-yr average of 9.19%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
26.90%
▲ above its 5-yr average of 12.70%
Return on assetsProfit on everything it owns
15.85%
▲ above its 5-yr average of 7.39%
Return on investmentProfit on long-term capital
23.39%
▲ above its 5-yr average of 11.48%
Return on capital employedProfit before interest and tax on equity + debt
26.58%

Growth Is the business getting bigger?

Revenue — last 12 months
+28.2%
▲ growing (off the scale)
Revenue — 3 yr, a year
+18.9%
▲ growing
Revenue — 5 yr, a year
+13.0%
▲ growing
Net profit — 3 yr, a year
+131.5%
▲ growing (off the scale)
Net profit — 5 yr, a year
+34.4%
▲ growing (off the scale)
EPS — last 12 months
+58.4%
▲ growing (off the scale)
EPS — 3 yr, a year
+131.3%
▲ growing (off the scale)
EPS — 5 yr, a year
+34.2%
▲ growing (off the scale)
Dividend — 3 yr, a year
+65.1%
▲ growing (off the scale)
Book value — 5 yr, a year
+10.1%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.29×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
1.90×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
1.39×
✓ Comfortable
Payout ratioShare of profit paid as dividend
15.46%
• Keeps most

Per share What each share stands for

EPS (TTM)
₹127.94
Book value
₹490.99
Cash flow
₹163.57
Dividend
₹18.00
Revenue
₹692.29

The share price is 4.20× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 110 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year17.97
Current Dividend Yield - Common Stock Primary Issue, LTM0.86
Price to Book - most recent fiscal year4.26
P/E Basic excluding extraordinary items - TTM18.86
P/E including extraordinary items - TTM16.35
P/E excluding extraordinary items low, trailing 12 months18.71
Price to Tangible Book - most fiscal year5.77
Dividend Yield - 5 Year Average0.63
Price to sales - most recent fiscal year3.42
Dividend Yield - indicated annual dividend divided by closing price0.86
Price to Cash Flow per share - trailing 12 month13.51
Peg Ratio0.12
Price to Free Cash Flow per Share - most recent fiscal year20.22
P/E Normalized, most recent fiscal year16.37
P/E excluding extraordinary items high, trailing 12 months463.08
P/E excluding extraordinary items, most recent fiscal year quarter16.35
Price to sales - trailing 12 month3.19
Net Debt, LFY−13,318.00

Per share

Dividend Per Share - 5 year average9.20
Cash Flow per share - trailing 12 month163.57
Cash Flow per share - most recent fiscal year144.50
EPS including extraordinary items - trailing 12 month127.94
EPS including extraordinary items - most recent fiscal year116.44
EBITD per share - trailing 12 month207.49
Revenue/share - trailing 12 month692.29
EPS excluding extraordinary items - trailing 12 month127.94
EPS Basic excluding extraordinary items - most recent fiscal year116.75
EPS Basic excluding extraordinary items - trailing 12 month128.25
Book value per share - most recent fiscal year491.02
Dividend per share - most recent fiscal year18.00
Revenue/share - most recent fiscal year610.45
EPS Normalized - most recent fiscal year127.78
Book value (tangible) per share - most recent fiscal year362.71
Dividends per share - trailing 12 month18.00
EPS excluding extraordinary items - most recent fiscal year116.44
Cash per share - most recent fiscal year173.85

Margins

Operating margin - trailing 12 month23.01
Gross Margin - 5 year average61.26
Operating margin - 1st historical fiscal year23.29
Operating Margin - 5 year average12.28
Net Profit Margin % - 1st historical fiscal year19.16
Gross Margin - 1st historical fiscal year68.75
Net Profit Margin % - trailing 12 month18.52
Net Profit Margin - 5 year average9.19
Pretax Margin - 5 year average12.20
Pretax margin - 1st historical fiscal year24.58
Pretax margin - trailing 12 month24.94
Free Operating Cash Flow/Revenue, 5 Year Average7.33
Gross Margin - trailing 12 month74.49

Growth

EPS Change %, TTM over TTM58.36
Revenue growth rate, 5 year13.02
EPS growth rate, 5 year34.23
Revenue Change % - most recent quarter 1 year ago32.04
Growth rate% - dividend, 3 year65.10
Growth rate% - EPS, 3 year131.28
Revenue/share (5 yr growth)12.88
Free Operating Cash Flow, 5 Year CAGR40.25
Tangible Book Value, Total Equity, 5 Year CAGR10.45
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR24.56
Capital Spending growth rate, 5 year24.84
Revenue Change %, TTM over TTM28.19
Growth rate% - Revenue, 3 year18.88
Book value per share growth rate, 5 year10.05
EPS Change % - most recent quarter 1 year ago16.04
Net Profit Margin growth rate, 5 year18.79
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR26.78
Total Debt, 5 Year CAGR5.22

Financial strength

Free Cash Flow - most recent fiscal year47,313.10
LT debt/equity - most recent fiscal year0.10
Quick ratio - most recent fiscal year1.39
Payout ratio - trailing 12 month14.88
Current ratio - most recent fiscal year1.90
Current EV/Free Cash Flow, LFY23.51
Total debt/total equity - most recent fiscal year0.29
Payout ratio - most recent fiscal year15.43

Returns & efficiency

Return on average equity - 5 year average12.70
Net Income/employee - trailing 12 month22,25,827.00
Revenue/employee - most recent fiscal year1,24,48,480.00
Return on investment - most recent fiscal year23.39
Return on average assets - most recent fiscal year15.85
Receivables turnover - most recent fiscal year4.62
Inventory turnover - most recent fiscal year1.43
Revenue/employee - trailing 12 month1,20,15,950.00
Return on average assets - 5 year average7.39
Net Income/employee - most recent fiscal year23,84,554.00
Asset turnover - most recent fiscal year0.83
Return on average equity - most recent fiscal year26.90
Return on investment - 5 year average11.48

Price & volume

Market Cap94,281.36
52 week Low Date28 Oct 2025
Price - 1 Day % Change−0.41
Relative (S&P500) price percent change - 13 week−6.86
Avg trading volume last 10 days0.64
Price - 13 week price percent change−10.73
Price - 52 week price percent change6.54
Avg Trading Volume Last 3 months18.96
Price - 5 Day % Change0.43
Price % Change Month To Date−4.41
Relative (S&P500) price percent change - 04 week0.73
52 week High Date16 Jul 2026
Price - 26 week price percent change−10.40
PDATE25 Sep 2026
Price - YTD price percent change−0.83
Relative (S&P500) price percent change - 52 week17.02
NPRICE2,092.00
Relative (S&P500) price percent change - 26 week−10.78
52 week Low1,900.00
52 week High2,529.50
Beta0.78
Relative (S&P500) price percent change - Year to Date14.37

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹18.00
  • Dividend yield0.87%
  • Payout ratio15.46%
  • 5-year average dividend₹9.20 a share
  • Latest dividend₹18.00 per share · 17 Jul 2026

Corporate calendar

  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹18.00 per share · 900% · Final dividend
  • BoardAudited Results & Final Dividend
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • BoardQuarterly Results & Others
  • MeetingPostal Ballot
Show 12 older events
  • MeetingAnnual General Meeting
  • BoardQuarterly Results & Others
  • Dividend₹12.00 per share · 600% · Final dividend
  • BoardAudited Results & Final Dividend
  • MeetingPostal Ballot
  • BoardQuarterly Results & Others
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹8.00 per share · 400% · Final dividend
  • Dividend₹4.00 per share · 200% · Final dividend
  • Dividend₹4.00 per share · 200% · Final dividend
  • Dividend₹6.50 per share · 325% · Final dividend

About Lupin

Biotechnology & Drugs

Lupin Limited is a pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. It has presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, GastroIntestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its ophthalmology portfolio includes over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals across European markets. Its diabetes brands include GIBTULIO, AJADUO, GIBTULIO MET, ONDERO, ONDERO MET, and Huminsulin.

Key people

  • Vinita D. GuptaChief Executive Officer, Executive Director
  • Ramesh SwaminathanExecutive Director, Global Chief Financial Officer, Chief Risk Officer and Head of API Plus SBU
  • Fabrice EgrosPresident - Corporate Development
  • Spiro GavarisPresident - US Generics
  • Claus JepsenPresident - Global Specialty
  • Cyrus KarkariaPresident - Biotech Business

Company facts

  • NSE symbolLUPIN
  • BSE code500257
  • ISININE326A01037
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 500
  • Market cap₹94,288 Cr
  • Revenue (FY26)₹27,958 Cr
  • Net profit (FY26)₹5,333 Cr

In the News

Recent headlines about Lupin — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Lupin (NSE: LUPIN) last traded at ₹2,062.00 on the NSE, down 1.43% (₹29.91) on the day, as of 28 Sep 2026. The day's range was ₹2,057.00 – ₹2,097.15.

Lupin's 52-week high is ₹2,530.00 (16 Jul 2026) and its 52-week low is ₹1,900.30 (28 Oct 2025). At ₹2,062.00 the share is 18.5% below its high and 8.5% above its low.

Lupin's market capitalisation is ₹94,288 Cr (₹94,288 Cr). It is part of the NIFTY 500 index.

Lupin's P/E ratio (trailing 12 months) is 17.05. The sector average is 33.72, so investors pay 49% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹127.94.

Lupin shares are up 7.41% over the last year, down 2.25% so far this year, down 11.68% over 6 months, down 12.01% over 3 months. Over the last year the stock did 17.02% better than the market.

In FY26 (year to Mar 2026), Lupin reported revenue of ₹27,958 Cr (up 23.12% on the year before) and a net profit of ₹5,333 Cr. Earnings per share were ₹116.44.

Yes. Lupin's latest dividend is ₹18.00 per share (900%, final dividend), with an ex-date of 17 Jul 2026. The dividend yield is 0.87%. It has paid 6 dividends in the records shown on this page.

As of Jun 2026: Promoter 46.85%, FII 22.42%, MF 14.84%, Other 15.89%. Promoter holding fell by 0.01 percentage points from Mar 2026.

Lupin's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

No. Lupin has debt — its debt-to-equity ratio is 0.29 and total debt was ₹6,616 Cr in FY26.